Compare BHM & GRML Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BHM | GRML |
|---|---|---|
| Founded | 2022 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | |
| Sector | Real Estate | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 35.5M | 29.2M |
| IPO Year | 2022 | 2022 |
| Metric | BHM | GRML |
|---|---|---|
| Price | $7.93 | $12.10 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $15.00 | N/A |
| AVG Volume (30 Days) | 1.7K | ★ 17.0M |
| Earning Date | 01-01-0001 | 05-13-2026 |
| Dividend Yield | ★ 4.54% | N/A |
| EPS Growth | N/A | ★ 31.25 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $68,734,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 36.88 | N/A |
| 52 Week Low | $8.02 | $0.16 |
| 52 Week High | $13.30 | $18.21 |
| Indicator | BHM | GRML |
|---|---|---|
| Relative Strength Index (RSI) | 41.09 | 64.56 |
| Support Level | N/A | $0.53 |
| Resistance Level | $8.97 | N/A |
| Average True Range (ATR) | 0.23 | 2.20 |
| MACD | -0.03 | 0.93 |
| Stochastic Oscillator | 1.90 | 60.01 |
Bluerock Homes Trust Inc owns and operates a portfolio of institutional residential properties including single-family homes, build-to-rent communities, and other residential communities located in attractive markets with a focus on the knowledge-economy and high-quality of life growth markets of the Sunbelt and Western United States. The company's principal objective is to generate attractive risk-adjusted returns on investments where it believes it can drive growth in funds from operations and net asset value by acquiring residential units, developing residential communities, and through value-add renovations. The company has two reportable segments, consisting of Residential Communities, which derives maximum revenue; and Scattered Single-family homes.
Greenland Mines Ltd develops essential medicines for the treatment of chronic diseases - cancer, cardiovascular, and neurodegenerative disorders. The Company operates as a single reporting segment focused on developing essential medicines for these chronic diseases. The Company has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and proprietary patented technologies involving melanocortin receptor-binding molecules and a gene therapy platform that introduces a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases.